WordNet

used to express refusal or denial or disagreement etc or especially to emphasize a negative statement; "no, you are wrong"
a negative; "his no was loud and clear"
referring to the degree to which a certain quality is present; "he was no heavier than a child" (同)no more
not in any degree or manner; not at all; "he is no better today"
quantifier; used with either mass nouns or plural count nouns for indicating a complete or almost complete lack or zero quantity of; "we have no bananas"; "no eggs left and no money to buy any"; "have you no decency?"; "did it with no help"; "Ill get you there in no time"
stated explicitly or in detail; "needed a specific amount"
a medicine that has a mitigating effect on a specific disease; "quinine is a specific for malaria"
(sometimes followed by `to'
being or affecting a disease produced by a particular microorganism or condition; used also of stains or dyes used in making microscope slides; "quinine is highly specific for malaria"; "a specific remedy"; "a specific stain is one having a specific affinity for particular structural elements"
relating to or distinguishing or constituting a taxonomic species; "specific characters"
of or relating to interstices
inflammation of the lungs; caused by a virus or an allergic reaction

PrepTutorEJDIC

《名詞の前に置いて》『一つも』(『一人も,少しも』)・・・『ない』 / 《補語につけて》『決して・・・でない』 / 《省略文で》・・・なし;・・・お断り / 《話》少ししか(あまり)・・・ない / (肯定の問いに対して)『いいえ』;(否定の問いに対して)はい,ええ / 《not, norの前に挿入して》『いや』,否 / 《形容詞の前に置その形容詞を否定して》…どころではない / 《比較級の前に置いて》ちっとも…でない,…と全く同じ / 《… or no の形で》…であってもなくても / 《驚き・困惑・不信などを表して》とんでもない / 《単数形で》『拒否』,「『いいえ』」という返事 / 《複数形で》反対[投]票
《名詞の前にのみ用いて》『特定の』,一定の・『明確な』,明白な・(そのものに)『特有の』,独特の《+『to』+『名』》・〈C〉(…の)特効薬《+『for』+『名』》・《複数形で》明細,細部(details)

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 非特異性間質性肺炎の原因、臨床症状、評価、診断causes clinical manifestations evaluation and diagnosis of nonspecific interstitial pneumonia [show details]
… insufficient for definitive diagnosis of a specific CTD . A multidisciplinary task force has proposed criteria for this entity, under the name "interstitial pneumonia with autoimmune features (IPAF)" . IPAF …
2. 非特異性間質性肺炎の治療法と予後treatment and prognosis of nonspecific interstitial pneumonia [show details]
… common pathway that is initiated by a spectrum of ILDs and that this phase of disease may respond to antifibrotic agents that are not disease-specific. Additional details of the trial and the use of nintedanib …
3. 間質性肺疾患の診断における肺生検の役割role of lung biopsy in the diagnosis of interstitial lung disease [show details]
… interstitial pneumonitis, interstitial pulmonary fibrosis that are insufficient to guide specific therapy . Acute exacerbations of fibrotic interstitial lung diseases have been… inconspicuous features suggestive of non-UIP pattern. The indeterminate UIP radiographic pattern is neither sensitive, nor specific for UIP or other alternative…
4. びまん性肺疾患（間質性肺炎）が生じた乳幼児や小児へのアプローチapproach to the infant and child with diffuse lung disease interstitial lung disease [show details]
… certain specific conditions (eg, Langerhans cell histiocytosis , pulmonary alveolar proteinosis or lysosomal storage disorders ), or disease mechanisms (eg, sarcoidosis or hypersensitivity pneumonitis ). …
5. 間質性肺疾患を有する成人に対するアプローチ：診断的検査approach to the adult with interstitial lung disease diagnostic testing [show details]
… associated with specific ILDs are discussed separately. The diagnostic approach to ILD relies on high-resolution computed tomography (HRCT) of the chest . Image acquisition should be tailored for ILD evaluation …

English Journal

Histopathology and exercise: a winning combination in pulmonary fibrosis: a case report.

Pisano V1, Fuschillo S, Balzano G.Author information 1Pulmonary Rehabilitation Unit, Fondazione Salvatore Maugeri, Istituto Scientifico di Telese, Telese Terme, Provincia di Benevento, Italy.AbstractThe diffuse parenchymal lung diseases form a heterogeneous group of disorders characterized by varying degrees of inflammation and fibrosis involving the space between epithelial and endothelial basement membranes. Among the diffuse parenchymal lung diseases of unknown etiology, one of the most common is usual interstitial pneumonia/idiopathic pulmonary fibrosis, which carries the worst prognosis. In contrast, nonspecific interstitial pneumonia, which belongs to the same diffuse parenchymal lung disease group, has a more favorable prognosis. Based on the relative amount of inflammation and fibrosis observed on lung biopsies, at least 2 nonspecific interstitial pneumonia patterns have been suggested: cellular and fibrosing. The long-term prognosis is excellent for patients with nonspecific interstitial pneumonia with a cellular pattern, as compared to patients with a fibrosing pattern. We describe here a patient with nonspecific interstitial pneumonia with a fibrosing pattern in a highly practiced runner, showing an unexpectedly long-term favorable course, and consider the possible role of exercise in the diagnosis and clinical course of the disease. This case reinforces the evidence that exercise training, which is a principal component of pulmonary rehabilitation, may have clinically important effects on functional exercise capacity, especially if it is delivered early in the course of the disease.
Respiratory care.Respir Care.2014 Mar;59(3):e31-4. doi: 10.4187/respcare.02520. Epub 2013 Aug 6.
The diffuse parenchymal lung diseases form a heterogeneous group of disorders characterized by varying degrees of inflammation and fibrosis involving the space between epithelial and endothelial basement membranes. Among the diffuse parenchymal lung diseases of unknown etiology, one of the most comm
PMID 23920216

Advanced glycation end-products and receptor for advanced glycation end-products expression in patients with idiopathic pulmonary fibrosis and NSIP.

Kyung SY1, Byun KH2, Yoon JY1, Kim YJ1, Lee SP1, Park JW1, Lee BH2, Park JS3, Jang AS3, Park CS3, Jeong SH1.Author information 1Department of Internal Medicine, Gachon University Gil Medical Center Incheon, Republic of Korea.2Department of Anatomy, Gachon University of Medicine and Science Incheon, Republic of Korea.3Genome Research Center for Allergy and Respiratory diseases, Soonchunhyang University Bucheon Hospital Bucheon, Republic of Korea.AbstractAdvanced glycation end products (AGEs) are associated with the pathogenesis of various diseases. AGEs induce excess accumulation of extracellular matrix and expression of profibrotic cytokines. In addition, studies on receptor for advanced glycation end products (RAGE) have shown that the ligand-RAGE interaction activates several intracellular signaling cascades associated with several fibrotic diseases. We investigated the expression of AGEs and RAGE in samples from patients with idiopathic pulmonary fibrosis (IPF) and non-specific interstitial pneumonia (NSIP). Lung tissues and plasma samples from patients with IPF (n=10), NSIP (n=10), and control subjects (n=10) were obtained. Expression of AGEs and RAGE was determined by immunofluorescence assay of lung tissue. Circulating AGEs were measured by Western blot and enzyme-linked immunosorbent assay. Lungs with IPF showed strong expression for both AGEs and RAGE compared to that in NSIP and controls. However, no difference in AGE or RAGE expression was observed in lungs with NSIP compared to that in the controls. Levels of circulating AGEs also increased significantly in lungs of patients with IPF compared to those with NSIP and normal control. Increased AGE-RAGE interaction may play an important role in the pathogenesis of IPF.
International journal of clinical and experimental pathology.Int J Clin Exp Pathol.2013 Dec 15;7(1):221-8. eCollection 2014.
Advanced glycation end products (AGEs) are associated with the pathogenesis of various diseases. AGEs induce excess accumulation of extracellular matrix and expression of profibrotic cytokines. In addition, studies on receptor for advanced glycation end products (RAGE) have shown that the ligand-RAG
PMID 24427342

MMP-7 and fcDNA serum levels in early NSCLC and idiopathic interstitial pneumonia: preliminary study.

Ulivi P1, Casoni GL, Foschi G, Scarpi E, Tomassetti S, Romagnoli M, Ravaglia C, Mengozzi M, Zoli W, Poletti V.Author information 1Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola 47014, Italy. p.ulivi@irst.emr.it.AbstractA non-invasive test to facilitate the diagnosis of non-small cell lung cancer (NSCLC) and idiopathic pulmonary fibrosis (IPF) is still not available and represents an important goal. Forty-eight patients with stage I NSCLC, 45 with IPF, 30 with other idiopathic interstitial pneumonias (IIPs) including idiopathic non-specific interstitial pneumonia (NSIP) and chronic hypersensitivity pneumonitis (HP), 35 with diffuse non-malignant disease and 30 healthy donors were enrolled onto the study. Free circulating (fc)DNA and MMP-7 levels were evaluated by Real Time PCR and ELISA, respectively. Median fcDNA levels were similar in NSCLC (127 ng/mL, range 23.6-345 ng/mL) and IPF (106 ng/mL, range 22-224 ng/mL) patients, and significantly lower in IIPs patients, in individuals with other diseases and in healthy donors (p < 0.05). Conversely, median MMP-7 values were significantly higher in IPF patients (9.10 ng/mL, range 3.88-19.72 ng/mL) than in those with NSCLC (6.31 ng/mL, range 3.38-16.36 ng/mL; p < 0.0001), NSIP (6.50 ng/mL, range 1.50-22.47 ng/mL; p = 0.007), other diseases (5.41 ng/mL, range 1.78-15.91, p < 0.0001) or healthy donors (4.35 ng/mL, range 2.45-7.23; p < 0.0001). Serum MMP-7 levels seem to be capable of distinguishing IPF patients from those with any other lung disease. fcDNA levels were similar in NSCLC and IPF patients, confirming its potential role as a biomarker, albeit non-specific, for the differential diagnosis of NSCLC.
International journal of molecular sciences.Int J Mol Sci.2013 Dec 11;14(12):24097-112. doi: 10.3390/ijms141224097.
A non-invasive test to facilitate the diagnosis of non-small cell lung cancer (NSCLC) and idiopathic pulmonary fibrosis (IPF) is still not available and represents an important goal. Forty-eight patients with stage I NSCLC, 45 with IPF, 30 with other idiopathic interstitial pneumonias (IIPs) includi
PMID 24336111